Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 62

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 62
---
:----------------------------------------|:----|:---------|--------:|:----|:---------|----------:|:----|:-----------------|-------------------:|
| Public and Private Placement Warrants   |     |          |   4,596 |     | $        | 23,000.00 |     |                  |               3.63 |
| February 2024 Series A Common Warrants  |     |          |     306 |     |          |  2,780.00 |     |                  |               2.12 |
| September 2024 Series C Common Warrants |     |          |   4,088 |     |          |      0.80 |     |                  |               2.71 |
| December 2024 Common Warrants           |     |          |   4,203 |     |          |    112.20 |     |                  |               2.98 |
| January 2025 Common Warrants            |     |          |   8,193 |     |          |    116.40 |     |                  |               3.02 |
| February 2025 Pre-funded Warrants       |     |          |  10,787 |     |          |     0.002 |     |                  | No expiration date |
| February 2025 Common Warrants           |     |          | 127,551 |     |          |     39.20 |     |                  |               4.61 |
| Outstanding as of June 30, 2025         |     |          | 159,724 |     | $        |    707.39 |     |                  |               4.40 |

<div align='center'>26</div>

NOTE 10 – FAIR VALUE MEASUREMENTS

Investment in equity securities

On
April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a
private placement (the “Fourth PIPE Financing”), 6,250 shares of its Series D Preferred Stock to investors in exchange for
the receipt of 1,000,279 shares of the Stella Series D Preferred Stock, in which a portion of the Stella Series D Preferred Stock was
owned by a related party investor (see Note 13). The exchange of shares was in lieu of cash, the cost of which is included in investment
in equity securities on the accompanying una